Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy
- 17 October 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 118 (1), 45-56
- https://doi.org/10.1007/s10549-008-0207-y
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- HER2and Responsiveness of Breast Cancer to Adjuvant ChemotherapyThe New England Journal of Medicine, 2006
- Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005Annals Of Oncology, 2005
- Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMFAnnals of Oncology, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000JNCI Journal of the National Cancer Institute, 2001
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upThe New England Journal of Medicine, 1995
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991